{"nctId":"NCT00434954","briefTitle":"Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes","startDateStruct":{"date":"2007-02"},"conditions":["Type 2 Diabetes Mellitus"],"count":494,"armGroups":[{"label":"Exenatide Twice Daily (BID)","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide twice daily (BID)"]},{"label":"Premixed Insulin Aspart Twice Daily (BID)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: premixed insulin aspart twice daily (BID)"]}],"interventions":[{"name":"exenatide twice daily (BID)","otherNames":["Byetta"]},{"name":"premixed insulin aspart twice daily (BID)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start\n* Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than 2 weeks within 3 months prior to study start, and have not received any insulin formulation for more than 14 days (other than in emergency situations) and within 14 days prior to study start\n* Have an HbA1c between 6.5% and 10.0%, inclusive\n* Have a body mass index (BMI) between 25 kg/m\\^2 and 40 kg/m\\^2, inclusive\n\nExclusion Criteria:\n\n* Have type 1 diabetes or known latent autoimmune diabetes in adults\n* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start\n* Are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)\n* Have used any prescription drug to promote weight loss within 3 months prior to study start\n* Have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry\n* Have previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Hemoglobin (HbA1c)","description":"Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.05"},{"groupId":"OG001","value":"-1.14","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c Target of < 6.5%","description":"Percentage of subjects achieving HbA1c target of \\< 6.5% at the end of study (week 26) \\[i.e., number of subjects who achieved HbA1c \\< 6.5% divided by total number of subjects times 100%\\].","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"24.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c Target of < 7.0%","description":"Percentage of subjects achieving HbA1c target of \\< 7.0% at the end of study (week 26) \\[i.e., number of subjects who achieved HbA1c \\< 7.0% divided by total number of subjects times 100%\\].","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycemic Episodes [Blood Glucose <= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)","description":"Risk for the first hypoglycemic episode to occur up to Week 26 (percentage of subjects who experienced at least one treatment-emergent hypoglycemic episode during the 26-week treatment period)\\[ i.e., number of subjects experiencing at least one hypoglycemic episode divided by total number of subjects times 100%\\]","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)","description":"Risk for first nocturnal (night-time) hypoglycemic episode to occur up to week 26 (percentage of subjects who experienced at least one episode of nocturnal hypoglycemia during the 26 week treatment period) \\[i.e., number of subjects who experienced nocturnal hypoglycemia divided by total number of subjects times 100%\\].","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"7 Point Self-monitored Blood Glucose (SMBG) Profiles","description":"7-point self-monitored blood glucose profiles at baseline and the end of the study, measured at 7 times during the day (pre-breakfast, 2 hours post-breakfast, pre-lunch, 2 hours post-lunch, pre-dinner, 2 hours post-dinner, and 3:00am).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.933","spread":"1.7138"},{"groupId":"OG001","value":"9.005","spread":"2.0432"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.774","spread":"1.7730"},{"groupId":"OG001","value":"7.293","spread":"1.3349"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.821","spread":"2.5306"},{"groupId":"OG001","value":"10.902","spread":"2.8499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.014","spread":"2.0557"},{"groupId":"OG001","value":"8.304","spread":"2.1212"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.443","spread":"2.1814"},{"groupId":"OG001","value":"8.357","spread":"2.3221"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.506","spread":"1.8800"},{"groupId":"OG001","value":"6.656","spread":"1.7011"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.698","spread":"2.2370"},{"groupId":"OG001","value":"9.899","spread":"2.6433"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.513","spread":"5.8997"},{"groupId":"OG001","value":"8.216","spread":"1.6108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.684","spread":"2.0059"},{"groupId":"OG001","value":"8.759","spread":"2.2174"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.616","spread":"2.1727"},{"groupId":"OG001","value":"7.194","spread":"1.5572"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.241","spread":"2.2880"},{"groupId":"OG001","value":"10.259","spread":"2.4868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.727","spread":"1.8820"},{"groupId":"OG001","value":"8.143","spread":"1.5614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.323","spread":"1.8692"},{"groupId":"OG001","value":"8.475","spread":"2.2643"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.518","spread":"1.5861"},{"groupId":"OG001","value":"6.999","spread":"1.5596"}]}]}]},{"type":"SECONDARY","title":"Blood Lipid Levels","description":"Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol (calculated), and triglyceride levels at baseline (week 0) and the end of the study (week 26)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.147","spread":"1.0008"},{"groupId":"OG001","value":"5.084","spread":"1.0079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.971","spread":"0.9653"},{"groupId":"OG001","value":"5.050","spread":"0.8933"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.234","spread":"0.3065"},{"groupId":"OG001","value":"1.255","spread":"0.3324"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.244","spread":"0.2805"},{"groupId":"OG001","value":"1.319","spread":"0.3394"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.845","spread":"0.8308"},{"groupId":"OG001","value":"2.768","spread":"0.8103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.738","spread":"0.8472"},{"groupId":"OG001","value":"2.852","spread":"0.8134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.391","spread":"1.5497"},{"groupId":"OG001","value":"2.410","spread":"1.4398"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.234","spread":"1.1886"},{"groupId":"OG001","value":"2.006","spread":"1.2040"}]}]}]},{"type":"PRIMARY","title":"Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)","description":"Risk for first hypoglycemic episode (blood glucose \\<=3.9 mmol/L or severe episode) to occur up to week 26","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline after 26 weeks of treatment (i.e., body weight at week 26 minus body weight at week 0)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":"0.22"},{"groupId":"OG001","value":"1.02","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline after 26 weeks of treatment (i.e., BMI at week 26 minus BMI at week 0)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.07"},{"groupId":"OG001","value":"0.32","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)","description":"Total DTSQ treatment satisfaction score at baseline (week 0) and after 26 weeks of treatment (LOCF). Total DTSQ treatment satisfaction score is derived as sum score of the individual components 1 and 4-8 of the DTSQ questionnaire. Each component is scored on a scale of 0 (worst case) to 6 (best case). Higher values represent higher treatment satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":"6.13"},{"groupId":"OG001","value":"29.7","spread":"6.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"6.05"},{"groupId":"OG001","value":"29.3","spread":"6.59"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcomes: Quality of Life (SF-12)","description":"SF-12 Physical and Mental Component Summary Scores at baseline (week 0) and after 26 weeks of treatment (LOCF). SF-12 Physical and Mental Component Summary Scores are normalized scores ranging from 0 (worst case) to 100 (best case), and are derived from responses to 12 questions. Scores \\> 50 indicate an above-average health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":"13.99"},{"groupId":"OG001","value":"36.3","spread":"14.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":"14.30"},{"groupId":"OG001","value":"37.7","spread":"14.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":"18.33"},{"groupId":"OG001","value":"28.3","spread":"19.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":"19.38"},{"groupId":"OG001","value":"29.6","spread":"18.36"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":247},"commonTop":["Nasopharyngitis","Nausea","Headache","Diarrhea","Vomiting"]}}}